Fast MDX - Model NGX 124 -Automated Molecular Diagnostics (MDX) Test Platform
The NGX 124 is a fully open, automated molecular diagnostics (MDx) test platform, offering a significant advantage over other systems. It supports all Laboratory Developed Tests (LDTs), Research Use Only (RUO), and approved assays sourced directly from a wide range of small and medium sized assay manufacturers.
Fast MDx aims to provide affordable MDx to all peoples of the world, regardless of income or location…
Compact, mobile and rugged on 4 lockable casters, Fast MDx can be used anywhere in the World. Small enough to fit through any doorway and into any elevator, Fast MDx is as much at home in a biosecure laboratory as it is in a hospital facility…
Jointly designed and developed by Fast MDx and Festo, the Fast MDx platform is the first fully automated, high-throughput, mobile Molecular Diagnostic (MDx) test platform and incorporates Fast MDx’s latest, ultra-fast, “NGx2” 4-Channel qPCR thermal cycler and Reverse Transcription “RT” block technology…
- Increased competition in the assay and reagent market, driving down costs.
- Economies of scale in reagent and assay production, further reducing expenses.
- Enhanced laboratory efficiency through streamlined automated testing.
- Elimination of manual handling errors via precise robotic liquid handling.
- User-friendly, intuitive interface, enabling a single technician to manage high-throughput testing, freeing up biomedical scientists for more complex tasks.
- Zero capital expenditure: the NGX 124 platform is provided free of charge, with a simple pay-per-test model.
- Flexible 3-month rolling contract with no long-term commitments.
- No maintenance, servicing, or warranty costs.
- Compact design, occupying just 0.7m2 of floor space, making it the smallest high-throughput platform.
- Up to 1,564 samples can be automatically tested in an 8 hour shift.